4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000044
Chief Executive Officer sold 18,055 shares at $28.96 ($522,873)
- Chief Executive Officer acquired 39,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Goff Brian · Chief Executive Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-02 | Exercise or conversion : show line 1 in the form 10b5-1 | +8,500 | 151,603 | D | ||
| 2026-03-02 | Sale : show line 2 in the form 10b5-1 | −3,870 | $28.96 | $112,075 | 147,733 | D |
| 2026-03-02 | Exercise or conversion : show line 3 in the form 10b5-1 | +18,000 | 165,733 | D | ||
| 2026-03-02 | Sale : show line 4 in the form 10b5-1 | −8,267 | $28.96 | $239,412 | 157,466 | D |
| 2026-03-02 | Exercise or conversion : show line 5 in the form 10b5-1 | +13,000 | 170,466 | D | ||
| 2026-03-02 | Sale : show line 6 in the form 10b5-1 | −5,918 | $28.96 | $171,385 | 164,548 | D |
| Open-market sales · 18,055 sh · avg $28.96 · $522,873 | ||||||
Table II: Derivative
5 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-01 | Grant or award : show line 7 in the form 10b5-1 Restricted stock units | +48,000 | 48,000 | D |
| 2026-03-01 | Grant or award : show line 8 in the form 10b5-1 Stock options (right to buy) | +174,000 | 174,000 | D |
| 2026-03-02 | Exercise or conversion : show line 9 in the form 10b5-1 Restricted stock units | −8,500 | 0 | D |
| 2026-03-02 | Exercise or conversion : show line 10 in the form 10b5-1 Restricted stock units | −18,000 | 18,000 | D |
| 2026-03-02 | Exercise or conversion : show line 11 in the form 10b5-1 Restricted stock units | −13,000 | 26,000 | D |
Loading xslF345X05/wk-form4_1772572669.xml…